CA2675445C - Improved culture of stem cells - Google Patents
Improved culture of stem cells Download PDFInfo
- Publication number
- CA2675445C CA2675445C CA2675445A CA2675445A CA2675445C CA 2675445 C CA2675445 C CA 2675445C CA 2675445 A CA2675445 A CA 2675445A CA 2675445 A CA2675445 A CA 2675445A CA 2675445 C CA2675445 C CA 2675445C
- Authority
- CA
- Canada
- Prior art keywords
- culture
- pluripotent stem
- cells
- agent
- stem cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 18
- 150000003384 small molecules Chemical class 0.000 claims abstract description 47
- 238000010367 cloning Methods 0.000 claims abstract description 41
- 238000004113 cell culture Methods 0.000 claims abstract description 30
- 239000002609 medium Substances 0.000 claims abstract description 27
- 239000001963 growth medium Substances 0.000 claims abstract description 18
- 239000003112 inhibitor Substances 0.000 claims abstract description 9
- 230000000977 initiatory effect Effects 0.000 claims abstract description 7
- 210000001778 pluripotent stem cell Anatomy 0.000 claims description 27
- 239000003795 chemical substances by application Substances 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 15
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 9
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 9
- 108010041788 rho-Associated Kinases Proteins 0.000 claims description 9
- 102000000568 rho-Associated Kinases Human genes 0.000 claims description 9
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 claims description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims description 5
- 239000001257 hydrogen Substances 0.000 claims description 5
- 239000006143 cell culture medium Substances 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 3
- 229940043355 kinase inhibitor Drugs 0.000 claims description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 3
- 239000003099 cyclic gmp dependent protein kinase inhibitor Substances 0.000 claims description 2
- 229940043437 protein kinase A inhibitor Drugs 0.000 claims description 2
- 239000012656 protein kinase A inhibitor Substances 0.000 claims description 2
- 125000004122 cyclic group Chemical group 0.000 claims 4
- 125000000547 substituted alkyl group Chemical group 0.000 claims 4
- 239000011248 coating agent Substances 0.000 claims 3
- 238000000576 coating method Methods 0.000 claims 3
- 238000012258 culturing Methods 0.000 claims 2
- 101710175516 14 kDa zinc-binding protein Proteins 0.000 claims 1
- 229940123924 Protein kinase C inhibitor Drugs 0.000 claims 1
- 239000003881 protein kinase C inhibitor Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 79
- 108091000080 Phosphotransferase Proteins 0.000 abstract description 6
- 102000020233 phosphotransferase Human genes 0.000 abstract description 6
- 230000035755 proliferation Effects 0.000 abstract description 4
- 241001465754 Metazoa Species 0.000 abstract description 2
- 210000001671 embryonic stem cell Anatomy 0.000 abstract 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 230000000694 effects Effects 0.000 description 11
- IDDDVXIUIXWAGJ-LJDSMOQUSA-N chembl1605605 Chemical compound Cl.Cl.C1C[C@@H]([C@H](N)C)CC[C@@H]1C(=O)NC1=CC=NC=C1 IDDDVXIUIXWAGJ-LJDSMOQUSA-N 0.000 description 10
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 9
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 8
- 239000003636 conditioned culture medium Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 6
- DZANYXOTJVLAEE-UHFFFAOYSA-N 6,8-difluoro-4-methylumbelliferyl phosphate Chemical compound FC1=C(OP(O)(O)=O)C(F)=CC2=C1OC(=O)C=C2C DZANYXOTJVLAEE-UHFFFAOYSA-N 0.000 description 5
- 102000003923 Protein Kinase C Human genes 0.000 description 5
- 108090000315 Protein Kinase C Proteins 0.000 description 5
- 102000004142 Trypsin Human genes 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 230000005757 colony formation Effects 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 4
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 4
- 238000010370 cell cloning Methods 0.000 description 4
- 108010082117 matrigel Proteins 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000011435 rock Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 3
- 101000669921 Homo sapiens Rho-associated protein kinase 2 Proteins 0.000 description 3
- 102000016349 Myosin Light Chains Human genes 0.000 description 3
- 108010067385 Myosin Light Chains Proteins 0.000 description 3
- 102100039314 Rho-associated protein kinase 2 Human genes 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001082 somatic cell Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- VHZOKTILAXIWHP-UHFFFAOYSA-N 1,4-diazepane;dihydrochloride Chemical compound Cl.Cl.C1CNCCNC1 VHZOKTILAXIWHP-UHFFFAOYSA-N 0.000 description 2
- 101100356682 Caenorhabditis elegans rho-1 gene Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102100035423 POU domain, class 5, transcription factor 1 Human genes 0.000 description 2
- 101710126211 POU domain, class 5, transcription factor 1 Proteins 0.000 description 2
- 102100032543 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Human genes 0.000 description 2
- 101710132081 Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN Proteins 0.000 description 2
- 102000010995 Pleckstrin homology domains Human genes 0.000 description 2
- 108050001185 Pleckstrin homology domains Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 101150111584 RHOA gene Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 239000000470 constituent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- -1 hydroxyl-HA-1077 Chemical compound 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 210000003518 stress fiber Anatomy 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- IZVFFXVYBHFIHY-UHFFFAOYSA-N (3alpha, 5alpha)-Cholest-7-en-3-ol, 9CI Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCCC(C)C)CCC33)C)C3=CCC21 IZVFFXVYBHFIHY-UHFFFAOYSA-N 0.000 description 1
- VAOSOCRJSSWBEQ-SPIKMXEPSA-N (z)-but-2-enedioic acid;2-piperazin-1-ylquinoline Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C1CNCCN1C1=CC=C(C=CC=C2)C2=N1 VAOSOCRJSSWBEQ-SPIKMXEPSA-N 0.000 description 1
- NXHKWHCUSVLFLP-UHFFFAOYSA-N 1-ethylisoquinoline-5-sulfonamide dihydrochloride Chemical compound Cl.Cl.C1=CC=C2C(CC)=NC=CC2=C1S(N)(=O)=O NXHKWHCUSVLFLP-UHFFFAOYSA-N 0.000 description 1
- GUGJQAFPKZZOIV-UHFFFAOYSA-N 2-[2-(isoquinolin-5-ylsulfonylamino)ethyl]guanidine;hydrochloride Chemical compound Cl.N1=CC=C2C(S(=O)(=O)NCCN=C(N)N)=CC=CC2=C1 GUGJQAFPKZZOIV-UHFFFAOYSA-N 0.000 description 1
- IDDDVXIUIXWAGJ-DDSAHXNVSA-N 4-[(1r)-1-aminoethyl]-n-pyridin-4-ylcyclohexane-1-carboxamide;dihydrochloride Chemical compound Cl.Cl.C1CC([C@H](N)C)CCC1C(=O)NC1=CC=NC=C1 IDDDVXIUIXWAGJ-DDSAHXNVSA-N 0.000 description 1
- MBZNIYPWRIDBOD-UHFFFAOYSA-N 5-piperazin-1-ylsulfonylisoquinoline;hydrochloride Chemical group Cl.C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCNCC1 MBZNIYPWRIDBOD-UHFFFAOYSA-N 0.000 description 1
- IZVFFXVYBHFIHY-SKCNUYALSA-N 5alpha-cholest-7-en-3beta-ol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@@H](CC[C@@]3([C@@H]([C@H](C)CCCC(C)C)CC[C@H]33)C)C3=CC[C@H]21 IZVFFXVYBHFIHY-SKCNUYALSA-N 0.000 description 1
- ADZYDUJXHKLXCN-UHFFFAOYSA-N 7alpha-obacunol Natural products CC12CCC3C4(C)C=CC(=O)OC(C)(C)C4CC(O)C3(C)C11OC1C(=O)OC2C=1C=COC=1 ADZYDUJXHKLXCN-UHFFFAOYSA-N 0.000 description 1
- ADHFMENDOUEJRK-UHFFFAOYSA-N 9-[(4-fluorophenyl)methyl]-n-hydroxypyrido[3,4-b]indole-3-carboxamide Chemical compound C1=NC(C(=O)NO)=CC(C2=CC=CC=C22)=C1N2CC1=CC=C(F)C=C1 ADHFMENDOUEJRK-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102100023755 Coiled-coil domain-containing protein 192 Human genes 0.000 description 1
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- CMKMGFAUKPAOMG-AWEZNQCLSA-N Glycyl-H-1152 Chemical compound C[C@H]1CN(C(=O)CN)CCCN1S(=O)(=O)C1=CC=CC2=CN=CC(C)=C12 CMKMGFAUKPAOMG-AWEZNQCLSA-N 0.000 description 1
- 101000978235 Homo sapiens Coiled-coil domain-containing protein 192 Proteins 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 241001482237 Pica Species 0.000 description 1
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 1
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 229940122975 Rho-associated kinase inhibitor Drugs 0.000 description 1
- 101150054980 Rhob gene Proteins 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- YOLMUJOPRUSEGJ-QRPNPIFTSA-N [2-(4-amino-1,2,5-oxadiazol-3-yl)-1-ethylimidazo[4,5-c]pyridin-7-yl]-[(3s)-3-aminopyrrolidin-1-yl]methanone;hydrochloride Chemical compound Cl.C=12N(CC)C(C=3C(=NON=3)N)=NC2=CN=CC=1C(=O)N1CC[C@H](N)C1 YOLMUJOPRUSEGJ-QRPNPIFTSA-N 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 230000009668 clonal growth Effects 0.000 description 1
- 230000001332 colony forming effect Effects 0.000 description 1
- 230000003436 cytoskeletal effect Effects 0.000 description 1
- 238000009795 derivation Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- LFVPBERIVUNMGV-UHFFFAOYSA-N fasudil hydrochloride Chemical compound Cl.C=1C=CC2=CN=CC=C2C=1S(=O)(=O)N1CCCNCC1 LFVPBERIVUNMGV-UHFFFAOYSA-N 0.000 description 1
- 238000007421 fluorometric assay Methods 0.000 description 1
- 210000001650 focal adhesion Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000012203 high throughput assay Methods 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002630 limonoids Chemical class 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- HBLCYSFLYMHCBM-UHFFFAOYSA-N n-(2-aminoethyl)isoquinoline-5-sulfonamide;dihydrochloride Chemical compound [Cl-].[Cl-].[NH+]1=CC=C2C(S(=O)(=O)NCC[NH3+])=CC=CC2=C1 HBLCYSFLYMHCBM-UHFFFAOYSA-N 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000022932 ruffle assembly Effects 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000002399 serotonin 2A agonist Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gynecology & Obstetrics (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Developmental Biology & Embryology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Reproductive Health (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88074707P | 2007-01-17 | 2007-01-17 | |
| US60/880,747 | 2007-01-17 | ||
| PCT/US2008/051347 WO2008089351A1 (en) | 2007-01-17 | 2008-01-17 | Improved culture of stem cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2675445A1 CA2675445A1 (en) | 2008-07-24 |
| CA2675445C true CA2675445C (en) | 2014-11-04 |
Family
ID=39277243
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2675445A Active CA2675445C (en) | 2007-01-17 | 2008-01-17 | Improved culture of stem cells |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US7892830B2 (enExample) |
| JP (1) | JP5419279B2 (enExample) |
| CA (1) | CA2675445C (enExample) |
| GB (1) | GB2458863B (enExample) |
| SE (1) | SE0950586L (enExample) |
| WO (1) | WO2008089351A1 (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4667241B2 (ja) * | 2003-06-27 | 2011-04-06 | 旭化成株式会社 | 細胞分化抑制剤、これを用いた細胞培養方法、培養液及び培養された細胞株 |
| EP1962719A4 (en) | 2005-08-29 | 2011-05-04 | Technion Res And Dev Of Foundation Ltd | MEDIA FOR BREEDING STEM CELLS |
| US8129187B2 (en) | 2005-12-13 | 2012-03-06 | Kyoto University | Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2 |
| US20090227032A1 (en) * | 2005-12-13 | 2009-09-10 | Kyoto University | Nuclear reprogramming factor and induced pluripotent stem cells |
| KR101420740B1 (ko) * | 2005-12-13 | 2014-07-17 | 교또 다이가꾸 | 핵초기화 인자 |
| US8278104B2 (en) * | 2005-12-13 | 2012-10-02 | Kyoto University | Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2 |
| DK3441459T3 (da) | 2006-08-02 | 2021-06-07 | Technion Res & Dev Foundation | Fremgangsmåder til ekspansion af embryonale stamceller i en suspensionskultur |
| JP2008099662A (ja) | 2006-09-22 | 2008-05-01 | Institute Of Physical & Chemical Research | 幹細胞の培養方法 |
| US9213999B2 (en) * | 2007-06-15 | 2015-12-15 | Kyoto University | Providing iPSCs to a customer |
| JP2008307007A (ja) * | 2007-06-15 | 2008-12-25 | Bayer Schering Pharma Ag | 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞 |
| ES2690554T3 (es) | 2008-03-17 | 2018-11-21 | The Scripps Research Institute | Enfoques químicos y genéticos combinados para la generación de células madre pluripotentes inducidas |
| WO2009116840A2 (en) * | 2008-03-21 | 2009-09-24 | Industry-Academic Cooperation Foundation, Yonsei University | Chemical reagents regulating stem cell fate |
| ES2722198T3 (es) | 2008-05-02 | 2019-08-08 | Univ Kyoto | Método de reprogramación nuclear |
| WO2009135206A1 (en) | 2008-05-02 | 2009-11-05 | Stem Cell Products, Inc. | Method for production of mast cells from stem cells |
| US8648170B2 (en) * | 2008-09-19 | 2014-02-11 | Wisconsin Alumni Research Foundation | Peptide-presenting surfaces for long-term culture of pluripotent cells |
| EP3260534A1 (en) * | 2008-11-20 | 2017-12-27 | Janssen Biotech, Inc. | Pluripotent stem cell culture on micro-carriers |
| ES2645869T3 (es) | 2008-12-17 | 2017-12-11 | The Scripps Research Institute | Generación y mantenimiento de células madre |
| US8642334B2 (en) | 2009-02-17 | 2014-02-04 | Memorial Sloan Kettering Cancer Center | Methods of neural conversion of human embryonic stem cells |
| JP6189581B2 (ja) * | 2009-02-20 | 2017-08-30 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | 幹細胞の分化のための方法および組成物 |
| WO2010107392A1 (en) * | 2009-03-20 | 2010-09-23 | Agency For Science, Technology And Research | Culture of pluripotent and multipotent cells on microcarriers |
| US8193235B2 (en) * | 2009-06-12 | 2012-06-05 | University Of Kansas | Compositions and methods for establishing and maintaining stem cells in an undifferentiated state |
| ES2638464T3 (es) * | 2009-10-16 | 2017-10-20 | The Scripps Research Institute | Inducción de células pluripotentes |
| CA2777552C (en) | 2009-10-19 | 2019-05-21 | Cellular Dynamics International, Inc. | Cardiomyocyte production |
| ES2539487T3 (es) * | 2009-11-04 | 2015-07-01 | Cellular Dynamics International, Inc. | Reprogramación episómica con compuestos químicos |
| CN102712896A (zh) * | 2009-11-06 | 2012-10-03 | Rnl生物技术株式会社 | 用于增殖毛囊干细胞的方法 |
| EP2499236B1 (en) | 2009-11-12 | 2020-01-01 | Technion Research & Development Foundation Ltd. | Culture media, cell cultures and methods of culturing pluripotent stem cells in an undifferentiated state |
| US10947499B2 (en) * | 2009-12-02 | 2021-03-16 | Research Development Foundation | Selection of stem cell clones with defined differentiation capabilities |
| AU2011235212B2 (en) | 2010-03-31 | 2014-07-31 | The Scripps Research Institute | Reprogramming cells |
| EP3399026B1 (en) | 2010-06-14 | 2024-06-26 | The Scripps Research Institute | Reprogramming of cells to a new fate |
| WO2012020845A1 (ja) * | 2010-08-09 | 2012-02-16 | 武田薬品工業株式会社 | 膵ホルモン産生細胞の製造法 |
| EP3056198A2 (en) * | 2010-09-16 | 2016-08-17 | MSP Co., Ltd | Use of compounds for inducing differentiation of mesenchymal stem cells to chondrocytes |
| US9181529B2 (en) | 2010-10-19 | 2015-11-10 | Cellular Dynamics International, Inc. | Titration of differentiation medium components |
| CN106893692B (zh) | 2010-12-22 | 2021-11-26 | 菲特治疗公司 | 用于单细胞分选与增强ipsc重新编程的细胞培养平台 |
| EP2676140A2 (en) * | 2011-02-14 | 2013-12-25 | Life Technologies Corporation | Substrates and methods for staining live cells |
| US9487752B2 (en) | 2011-03-30 | 2016-11-08 | Cellular Dynamics International, Inc. | Priming of pluripotent stem cells for neural differentiation |
| JP2014520551A (ja) | 2011-07-11 | 2014-08-25 | セルラー ダイナミクス インターナショナル， インコーポレイテッド | 細胞のリプログラミング方法およびゲノムの改変方法 |
| CN110684734A (zh) | 2011-11-04 | 2020-01-14 | 纪念斯隆-凯特琳癌症中心 | 用于植入的中脑多巴胺（da）神经元 |
| WO2013082268A1 (en) | 2011-11-30 | 2013-06-06 | The Wistar Institute Of Anatomy And Biology | Methods and compositions for regulation of cell aging, carcinogenesis, and reprogramming |
| US10266807B2 (en) | 2013-04-03 | 2019-04-23 | FUJIFILM Cellular Dynamics, Inc. | Methods and compositions for culturing endoderm progenitor cells in suspension |
| EP3498824A1 (en) | 2013-04-26 | 2019-06-19 | Memorial Sloan-Kettering Cancer Center | Cortical interneurons and other neuronal cells produced by the directed differentiation of pluripotent and multipotent cells |
| SG10201807292YA (en) | 2014-03-04 | 2018-09-27 | Fate Therapeutics Inc | Improved reprogramming methods and cell culture platforms |
| ES2939807T3 (es) | 2014-03-21 | 2023-04-27 | Fujifilm Cellular Dynamics Inc | Producción de neuronas dopaminérgicas del mesencéfalo y métodos para su utilización |
| EP3183338B1 (en) | 2014-08-19 | 2020-03-04 | FUJIFILM Cellular Dynamics, Inc. | Neural networks formed from cells derived from pluripotent stem cells |
| EP3207122B1 (en) | 2014-10-14 | 2019-05-08 | FUJIFILM Cellular Dynamics, Inc. | Generation of keratinocytes from pluripotent stem cells and maintenance of keratinocyte cultures |
| AU2016338680B2 (en) | 2015-10-16 | 2022-11-17 | Fate Therapeutics, Inc. | Platform for the induction and maintenance of ground state pluripotency |
| AU2016341982B2 (en) | 2015-10-21 | 2022-07-07 | Indiana University Research And Technology Corporation | Methods of generating human inner ear sensory epithelia and sensory neurons |
| JP7018875B2 (ja) | 2015-10-21 | 2022-02-14 | インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション | 多能性幹細胞からのヒト皮膚オルガノイドの誘導 |
| TWI812584B (zh) | 2015-10-30 | 2023-08-21 | 美國加利福尼亞大學董事會 | 從幹細胞產生t細胞之方法及使用該t細胞之免疫療法 |
| EP3438248A4 (en) * | 2016-03-30 | 2019-11-06 | Kyowa Hakko Bio Co., Ltd. | NAIVES PLURIPOTENT STEM CELL CULTIVATION MEDIUM AND PLURIPOTENT STEM CELL CULTIVATION PROCEDURE |
| WO2018035214A1 (en) | 2016-08-16 | 2018-02-22 | Cellular Dynamics International., Inc. | Methods for differentiating pluripotent cells |
| US11767508B2 (en) | 2017-07-24 | 2023-09-26 | Wisconsin Alumni Research Foundation | Methods and culture substrates for controlled induction of biomimetic neural tissues comprising singular rosette structures |
| WO2020047380A1 (en) | 2018-08-31 | 2020-03-05 | Wisconsin Alumni Research Foundation | Generating arterial endothelial cell-seeded vascular grafts |
| US20240219375A1 (en) | 2021-04-07 | 2024-07-04 | FUJIFILM Cellular Dynamics, Inc. | Dopaminergic precursor cells and methods of use |
| CN118339279A (zh) | 2021-10-29 | 2024-07-12 | 富士胶片细胞动力公司 | 包含突变的多巴胺能神经元及其使用方法 |
| WO2025097051A1 (en) | 2023-11-03 | 2025-05-08 | Axent Biosciences Inc. | Thermoreversible polymers with improved stability and methods and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4456757A (en) | 1981-03-20 | 1984-06-26 | Asahi Kasei Kogyo Kabushiki Kaisha | Isoquinolinesulfonyl derivatives and process for the preparation thereof |
| WO1997028130A1 (en) | 1996-02-02 | 1997-08-07 | Nippon Shinyaku Co., Ltd. | Isoquinoline derivatives and drugs |
| ES2286834T5 (es) | 1996-08-12 | 2011-01-31 | Mitsubishi Tanabe Pharma Corporation | Medicamentos que comprenden un inhibidor de la rho quinasa. |
| US7439064B2 (en) | 2000-03-09 | 2008-10-21 | Wicell Research Institute, Inc. | Cultivation of human embryonic stem cells in the absence of feeder cells or without conditioned medium |
| US20020009713A1 (en) * | 2000-05-11 | 2002-01-24 | Miller Freda D. | Methods for identifying modulators of neuronal growth |
| WO2003080649A2 (en) * | 2002-03-20 | 2003-10-02 | Regents Of The University Of Minnesota | Induction of hepatocyte proliferation in vitro by inhibition of cell cycle inhibitors |
| CA2517959A1 (en) * | 2003-03-07 | 2004-09-16 | Gamida-Cell Ltd. | Expansion of renewable stem cell populations using modulators of pi 3-kinase |
| US7829332B2 (en) * | 2004-02-13 | 2010-11-09 | Cornell Research Foundation, Inc. | Purines are self-renewal signals for neural stem cells, and purine receptor antagonists promote neuronal and glial differentiation therefrom |
| JP4576545B2 (ja) * | 2004-05-27 | 2010-11-10 | 独立行政法人理化学研究所 | 羊膜由来因子による胚性幹細胞の培養方法 |
| EP1791952A4 (en) * | 2004-08-13 | 2008-06-11 | Univ Georgia Res Found | COMPOSITIONS AND METHODS OF SELF-RENEWAL AND DIFFERENTIATION IN HUMAN EMBRYONAL STEM CELLS |
| ES2383813T3 (es) | 2004-09-08 | 2012-06-26 | Wisconsin Alumni Research Foundation | Método de cultivo y cultivo de células madre embrionarias |
| US7442548B2 (en) | 2004-09-08 | 2008-10-28 | Wisconsin Alumni Research Foundation | Culturing human embryonic stem cells in medium containing pipecholic acid and gamma amino butyric acid |
| US7641897B2 (en) * | 2004-11-23 | 2010-01-05 | The Board Of Trustees Of The Leland Stanford Junior University | Feeder layer and serum independent embryonic stem cells |
| ITVA20060041A1 (it) | 2006-07-05 | 2008-01-06 | Dialectica Srl | Uso di composti derivati amminotiazolici, di loro composizioni farmaceutiche, nel trattamento di malattie caratterizzate dalla anormale repressione della trascrizione genica, particolarmente il morbo di huntington |
| CA2658764A1 (en) | 2006-07-20 | 2008-01-24 | Mehmet Kahraman | Benzothiophene inhibitors of rho kinase |
| JP2008099662A (ja) * | 2006-09-22 | 2008-05-01 | Institute Of Physical & Chemical Research | 幹細胞の培養方法 |
-
2008
- 2008-01-17 JP JP2009546511A patent/JP5419279B2/ja active Active
- 2008-01-17 SE SE0950586A patent/SE0950586L/sv not_active Application Discontinuation
- 2008-01-17 GB GB0914193A patent/GB2458863B/en active Active
- 2008-01-17 CA CA2675445A patent/CA2675445C/en active Active
- 2008-01-17 US US12/016,066 patent/US7892830B2/en active Active
- 2008-01-17 WO PCT/US2008/051347 patent/WO2008089351A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008089351A1 (en) | 2008-07-24 |
| US7892830B2 (en) | 2011-02-22 |
| CA2675445A1 (en) | 2008-07-24 |
| GB2458863B (en) | 2011-10-12 |
| JP5419279B2 (ja) | 2014-02-19 |
| SE0950586L (sv) | 2009-08-13 |
| GB0914193D0 (en) | 2009-09-16 |
| US20080171385A1 (en) | 2008-07-17 |
| JP2010516255A (ja) | 2010-05-20 |
| GB2458863A (en) | 2009-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2675445C (en) | Improved culture of stem cells | |
| US10711250B2 (en) | Ex vivo proliferation of epithelial cells | |
| RU2555538C2 (ru) | Культура плюрипотентных стволовых клеток на микроносителях | |
| US10100285B2 (en) | Ex vivo proliferation of epithelial cells | |
| EP3438248A1 (en) | Naïve pluripotential stem cell culturing medium and pluripotential stem cell culturing method | |
| WO2014078414A1 (en) | Chemically defined production of cardiomyocytes from pluripotent stem cells | |
| CN111684058B (zh) | 从多能干细胞向肠上皮细胞的分化诱导方法 | |
| CN102428172A (zh) | 多潜能和多能细胞在微载体上的培养 | |
| JP2025072608A (ja) | 細胞培養のための組成物および方法 | |
| US20220267736A1 (en) | Pluripotent stem cell aggregation suppressor | |
| US20240384232A1 (en) | Clinical-grade therapeutic progenitors generated from tankyrase/parp-inhibited pluripotent stem cell banks | |
| US20220282219A1 (en) | Genetically engineered human fetal liver niche as platform for biomanufacturing of hematopoietic stem cells | |
| Zhang et al. | Protein kinase A inhibitor, H89, enhances survival and clonogenicity of dissociated human embryonic stem cells through Rho-associated coiled-coil containing protein kinase (ROCK) inhibition | |
| De Los Angeles et al. | ERK-independent African Green monkey pluripotent stem cells in a putative chimera-competent state | |
| CN115516084A (zh) | T细胞祖细胞的制造方法 | |
| JP2023106639A (ja) | 内耳前駆細胞の製造方法、内耳有毛細胞の製造方法、薬剤の評価方法、及び内耳細胞分化誘導用組成物 | |
| JP2021126066A (ja) | 細胞凝集抑制剤 | |
| Chen et al. | Effect of dual‐specificity protein phosphatase 5 on pluripotency maintenance and differentiation of mouse embryonic stem cells | |
| KR20250038692A (ko) | At2 세포로 분화시키는 방법 | |
| Zandi et al. | Optimization of buffalo (Bubalus bubalis) embryonic stem cell culture system | |
| JP2023106640A (ja) | 内耳有毛細胞の製造方法、薬剤の評価方法、及び細胞分化誘導用組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20130115 |